A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Informazioni relative al progetto

SenseGuard

ID dell’accordo di sovvenzione: 946598

DOI

10.3030/946598

Progetto chiuso

Data della firma CE 26 Marzo 2020

Data di avvio 1 Aprile 2020

Data di completamento 31 Marzo 2023

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 3 567 185,00

Contributo UE

€ 2 497 029,50

Coordinato da

NanoVation-GS
Israel

Periodic Reporting for period 2 - SenseGuard (A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors)

Periodo di rendicontazione: 2021-04-01 al 2023-03-31

Sintesi del contesto e degli obiettivi generali del progetto

Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become the third leading causes of death by 2030. Nevertheless, COPD patients lack of a frequent and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.
To address this massive, worldwide problem, NanoVation’s goal – during the EIC Accelerator project - is to market a clinically validated SenseGuard™. SenseGuard™ is a breakthrough solution, for reliably monitoring of patients with respiratory diseases, including COPD, leveraging a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

NanoVation has finalised the new generation design and developed the hardware and software for optimum performance. The company has also increased its production capacity, meeting its daily production target. NanoVation has commenced the validation activities (including patient recruitment for the clinical trials) and will continue to focus on it in the upcoming months.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Chronic respiratory diseases such as COPD, receive little attention and funding in comparison with other major causes of global morbidity and mortality. Accurate, constant monitoring of COPD patients is crucial to manage exacerbation and minimise outcome severity and costly intervention. Once commercialised, SenseGuard™ will contribute to effective management, therapies and treatment, which will also lead to decreased healthcare costs. By remotely monitoring COPD patients at home, SenseGuard™ will help to reduce admissions in hospitals and thus associated costs for healthcare facilities, thanks to early detection and timely intervention.

nv-logo-new.png